French Investor Leads €60M Financial Round for the Future of DNA Synthesis

27/01/2016 - 3 minutes

Twist Bioscience is a San Francisco Biotech accelerating science and innovation through rapid, high-quality DNA synthesis piece of tech. And now, Twist has completed a $61 million Series D round.

An improved silicon-based design compared to the traditional 96-well plates could do wonders for DNA synthesis, including major improvements in cost and time of the process. And the potential applications of synthetic DNA are vast, to include test cycles in personalized medicine, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics, biodetection and data storage.

So this proprietary synthetic DNA manufacturing process from Twist features a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. It could also potentially be used to produce synthetic RNA, which is a growing area of therapeutic R&D in Biotech. Read more about the tech on Wired.

To date, Twist has shipped 65 million base pairs of DNA to more than 100 customers using its high-throughput gene fabrication platform. Now,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member